60 Degrees Pharmaceuticals, Inc. SXTP

SXTP Company Overview

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of medicines for infectious diseases, with a particular emphasis on malaria and other diseases affecting travelers, military personnel, and populations in tropical or underserved regions. The company operates within the biopharmaceutical and anti-infective therapeutics industries and is publicly traded on the Nasdaq Capital Market under the ticker SXTP. Its primary commercial product is ARAKODA® (tafenoquine), an FDA-approved antimalarial drug indicated for malaria prophylaxis in adults.

The company’s business model combines commercialization of approved therapeutics with development-stage research programs targeting infectious diseases and immune-related conditions. Revenue generation has historically been driven primarily by product sales, licensing arrangements, and government-related opportunities associated with infectious disease preparedness. The company traces its origins to efforts focused on tropical medicine and military health applications, evolving into a publicly traded pharmaceutical enterprise with a portfolio centered on infectious disease therapeutics and strategic collaborations involving drug development and commercialization.